Status:
UNKNOWN
Real-world Data of Ocrelizumab in Multiple Sclerosis in LATAM
Lead Sponsor:
Hospital Italiano de Buenos Aires
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
Brief Summary
It has been almost 25 years since the publication of the pivotal trial results for the first disease-modifying therapy (DMT) for RRMS. Currently disease modifying therapies (DMTs) for MS approved by t...
Detailed Description
Multiple sclerosis is a chronic inflammatory disease of the CNS that leads to focal plaques of primary demyelination and diffuse neurodegeneration in the grey and white matter of the brain and spinal ...
Eligibility Criteria
Inclusion
- \- multiple sclerosis patients that received ocrelizumab
Exclusion
- \-
Key Trial Info
Start Date :
February 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03784547
Start Date
February 1 2019
End Date
September 1 2019
Last Update
August 9 2019
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Juan Ignacio Rojas
Buenos Aires, Argentina, 1453
2
Juan Ignacio Rojas
Buenos Aires, Argentina, 1453
3
Juan Ignacio Rojas
Buenos Aires, Argentina, 1453
4
Edgard Carnero
Buenos Aires, Argentina